Biomarkers for chronic fatigue

Abstract Fatigue that persists for 6 months or more is termed chronic fatigue. Chronic fatigue (CF) in combination with a minimum of 4 of 8 symptoms and the absence of diseases that could explain these symptoms, constitute the case definition for chronic fatigue syndrome/myalgic encephalomyelitis (C...

Full description

Saved in:
Bibliographic Details
Published in:Brain, behavior, and immunity behavior, and immunity, 2012-11, Vol.26 (8), p.1202-1210
Main Authors: Klimas, Nancy G, Broderick, Gordon, Fletcher, Mary Ann
Format: Article
Language:English
Subjects:
Allergy and Immunology
Animals
Autonomic nervous system
biomarkers
Biomarkers - metabolism
Chronic Disease
chronic fatigue syndrome
Fatigue
Fatigue - diagnosis
Fatigue - immunology
Fatigue - metabolism
Fatigue - physiopathology
Fatigue Syndrome, Chronic - immunology
Fatigue Syndrome, Chronic - metabolism
Fatigue Syndrome, Chronic - physiopathology
Humans
Hypothalamic-pituitary-adrenal axis
Immune system
Inflammation
Inflammation - immunology
Inflammation - metabolism
Myalgic encephalomyelitis
Psychiatry
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Fatigue that persists for 6 months or more is termed chronic fatigue. Chronic fatigue (CF) in combination with a minimum of 4 of 8 symptoms and the absence of diseases that could explain these symptoms, constitute the case definition for chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). Inflammation, immune system activation, autonomic dysfunction, impaired functioning in the hypothalamic-pituitary-adrenal axis, and neuroendocrine dysregulation have all been suggested as root causes of fatigue. The identification of objective markers consistently associated with CFS/ME is an important goal in relation to diagnosis and treatment, as the current case definitions are based entirely on physical signs and symptoms. This review is focused on the recent literature related to biomarkers for fatigue associated with CFS/ME and, for comparison, those associated with other diseases. These markers are distributed across several of the body’s core regulatory systems. A complex construct of symptoms emerges from alterations and/or dysfunctions in the nervous, endocrine and immune systems. We propose that new insight will depend on our ability to develop and deploy an integrative profiling of CFS/ME pathogenesis at the molecular level. Until such a molecular signature is obtained efforts to develop effective treatments will continue to be severely limited.
ISSN:0889-1591
1090-2139
DOI:10.1016/j.bbi.2012.06.006